Jasper van der Lugt

Summary

Affiliation: The HIV Netherlands Australia Thailand Research Collaboration
Country: Thailand

Publications

  1. doi request reprint Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naive HIV-1-infected adults
    Jasper van der Lugt
    HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Center Bangkok, 104 Ratchadamri Road, Pathumwan, Bangkok 10330, Thailand
    J Antimicrob Chemother 61:1145-53. 2008
  2. doi request reprint Reducing the boosting dose of ritonavir does not affect saquinavir plasma concentrations in HIV-1-infected individuals
    Jasper van der Lugt
    The HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
    AIDS 23:1176-9. 2009
  3. ncbi request reprint The pharmacokinetics, safety and efficacy of boosted saquinavir tablets in HIV type-1-infected pregnant women
    Jasper van der Lugt
    The HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
    Antivir Ther 14:443-50. 2009
  4. doi request reprint Plasma concentrations of generic lopinavir/ritonavir in HIV type-1-infected individuals
    Jasper van der Lugt
    The HIV Netherlands Australia Thailand Research Collaboration HIV NAT, Thai Red Cross Aids Research Centre TRCARC, Bangkok, Thailand
    Antivir Ther 14:1001-4. 2009
  5. ncbi request reprint Pharmacokinetics and 48 week efficacy of adjusted dose indinavir/ritonavir in rifampicin-treated HIV/tuberculosis-coinfected patients: a pilot study
    Anchalee Avihingsanon
    HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Center, Pathumwan, Bangkok, Thailand
    AIDS Res Hum Retroviruses 28:1170-6. 2012
  6. doi request reprint Pharmacokinetics and 48-week safety and efficacy of generic lopinavir/ritonavir in Thai HIV-infected patients
    Reshmie A Ramautarsing
    The HIV Netherlands Australia Thailand Research Collaboration HIV NAT, Bangkok, Thailand
    Antivir Ther 18:249-52. 2013
  7. pmc Short communication: Aging not gender is associated with high atazanavir plasma concentrations in Asian HIV-infected patients
    Anchalee Avihingsanon
    1 HIV Netherlands Australia Thailand HIV NAT Research Collaboration, Thai Red Cross AIDS Research Center Bangkok, Bangkok, Thailand
    AIDS Res Hum Retroviruses 29:1541-6. 2013
  8. ncbi request reprint Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children
    Thanyawee Puthanakit
    HIV Netherlands Australia Thailand Research Collaboration HIV NAT, Bangkok, Thailand
    J Antimicrob Chemother 64:1080-6. 2009
  9. doi request reprint Thai HIV-1-infected women do not require a dose increase of lopinavir/ritonavir during the third trimester of pregnancy
    Reshmie A Ramautarsing
    The HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
    AIDS 25:1299-303. 2011
  10. doi request reprint Neither branded nor generic lopinavir/ritonavir produces adequate lopinavir concentrations at a reduced dose of 200/50 mg twice daily
    Reshmie A Ramautarsing
    The HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
    J Acquir Immune Defic Syndr 59:55-8. 2012

Detail Information

Publications12

  1. doi request reprint Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naive HIV-1-infected adults
    Jasper van der Lugt
    HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Center Bangkok, 104 Ratchadamri Road, Pathumwan, Bangkok 10330, Thailand
    J Antimicrob Chemother 61:1145-53. 2008
    ..To study the pharmacokinetics and short-term efficacy of low and standard dose lopinavir/ritonavir and saquinavir combinations in Thai, human immunodeficiency virus (HIV)-infected, treatment-naive patients...
  2. doi request reprint Reducing the boosting dose of ritonavir does not affect saquinavir plasma concentrations in HIV-1-infected individuals
    Jasper van der Lugt
    The HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
    AIDS 23:1176-9. 2009
    ..The 50% reduction of ritonavir boosting did not result in a change in the pharmacokinetics of saquinavir, whereas the ritonavir exposure was significantly lower when a dose of 50 mg was administered...
  3. ncbi request reprint The pharmacokinetics, safety and efficacy of boosted saquinavir tablets in HIV type-1-infected pregnant women
    Jasper van der Lugt
    The HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
    Antivir Ther 14:443-50. 2009
    ..Pregnancy affects the pharmacokinetics of most protease inhibitors. Saquinavir, when administered in a tablet formulation, has not been studied extensively in this setting...
  4. doi request reprint Plasma concentrations of generic lopinavir/ritonavir in HIV type-1-infected individuals
    Jasper van der Lugt
    The HIV Netherlands Australia Thailand Research Collaboration HIV NAT, Thai Red Cross Aids Research Centre TRCARC, Bangkok, Thailand
    Antivir Ther 14:1001-4. 2009
    ..However quality and safety remains an issue of concern. Therefore, we evaluated minimal plasma concentrations and short-term safety of a generic lopinavir/ritonavir 200/50 mg tablet formulation...
  5. ncbi request reprint Pharmacokinetics and 48 week efficacy of adjusted dose indinavir/ritonavir in rifampicin-treated HIV/tuberculosis-coinfected patients: a pilot study
    Anchalee Avihingsanon
    HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Center, Pathumwan, Bangkok, Thailand
    AIDS Res Hum Retroviruses 28:1170-6. 2012
    ..Despite good virological outcome in our cohort, prolonged exposure to subtherapeutic indinavir concentrations may lead to treatment failure...
  6. doi request reprint Pharmacokinetics and 48-week safety and efficacy of generic lopinavir/ritonavir in Thai HIV-infected patients
    Reshmie A Ramautarsing
    The HIV Netherlands Australia Thailand Research Collaboration HIV NAT, Bangkok, Thailand
    Antivir Ther 18:249-52. 2013
    ..We assessed pharmacokinetics, safety and efficacy of generic lopinavir/ritonavir (LPV/r) produced by the Government Pharmaceutical Organization (GPO) of Thailand in Thai HIV-infected adults...
  7. pmc Short communication: Aging not gender is associated with high atazanavir plasma concentrations in Asian HIV-infected patients
    Anchalee Avihingsanon
    1 HIV Netherlands Australia Thailand HIV NAT Research Collaboration, Thai Red Cross AIDS Research Center Bangkok, Bangkok, Thailand
    AIDS Res Hum Retroviruses 29:1541-6. 2013
    ..Patients from the aging group appeared to have higher atazanavir exposure compared to the younger group. Further PK explorations of ATV in the extremely aged population are warranted...
  8. ncbi request reprint Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children
    Thanyawee Puthanakit
    HIV Netherlands Australia Thailand Research Collaboration HIV NAT, Bangkok, Thailand
    J Antimicrob Chemother 64:1080-6. 2009
    ..Several studies have shown higher plasma concentrations of antiretroviral agents in Thai adults than in Caucasians, suggesting that lower doses may be used...
  9. doi request reprint Thai HIV-1-infected women do not require a dose increase of lopinavir/ritonavir during the third trimester of pregnancy
    Reshmie A Ramautarsing
    The HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
    AIDS 25:1299-303. 2011
    ..To investigate whether Thai HIV-1-infected pregnant women require a dose increase of lopinavir/ritonavir (LPV/r) and to assess the safety and efficacy of the generic tablets during pregnancy...
  10. doi request reprint Neither branded nor generic lopinavir/ritonavir produces adequate lopinavir concentrations at a reduced dose of 200/50 mg twice daily
    Reshmie A Ramautarsing
    The HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
    J Acquir Immune Defic Syndr 59:55-8. 2012
    ..All patients remained virologically suppressed at week 12. In conclusion, LPV/r 200/50mg BID does not lead to adequate lopinavir plasma concentrations. Generic and branded LPV/r have comparable PK-parameters...
  11. ncbi request reprint Safety and efficacy of a double-boosted protease inhibitor combination, saquinavir and lopinavir/ritonavir, in pretreated children at 96 weeks
    Torsak Bunupuradah
    The HIV Netherlands Australia Thailand Research Collaboration HIV NAT, Bangkok, Thailand
    Antivir Ther 14:241-8. 2009
    ....
  12. pmc Cognitive function and neurodevelopmental outcomes in HIV-infected Children older than 1 year of age randomized to early versus deferred antiretroviral therapy: the PREDICT neurodevelopmental study
    Thanyawee Puthanakit
    HIV NAT, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand
    Pediatr Infect Dis J 32:501-8. 2013
    ..We now report neurodevelopmental outcomes...